Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03116529 · ClinicalTrials.gov registry record · Phase 1
Neoadjuvant Durvalumab and Tremelimumab Plus Radiation for High Risk Soft-Tissue Sarcoma
A Phase 1 study, sponsored by University of Maryland, Baltimore.
- Terminated
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT03116529 is a Phase 1 study that was terminated before completion, run by University of Maryland, Baltimore. The registered enrollment target is 22 participants.
The verdict
NCT03116529, a Phase 1 study, was terminated before completion, sponsored by University of Maryland, Baltimore.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
Chemotherapy is controversial for soft tissue sarcoma that has not yet metastasized. Surgery and radiation are effective for local control, but there are no highly effective interventions to prevent metastatic spread of soft tissue sarcoma. Immunotherapy has shown promise in other types of cancer. Combining two types of immunotherapy agents with preoperative radiation may help the immune system recognize the sarcoma and stimulate an anti-tumor immune response.
Interventions
- COMBINATION_PRODUCT Combination Radiation, Immunotherapy, Surgery
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2017-06-21 |
| Est. Completion | 2024-06-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03116529
The ClinicalTrials.gov registry entry for NCT03116529 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Combination Radiation, Immunotherapy, Surgery is the first listed.
NCT03116529 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03116529 about?
NCT03116529 is a clinical study titled "Neoadjuvant Durvalumab and Tremelimumab Plus Radiation for High Risk Soft-Tissue Sarcoma". Chemotherapy is controversial for soft tissue sarcoma that has not yet metastasized. Surgery and radiation are effective for local control, but there are no highly effective interventions to prevent metastatic spread of soft tissue sarcoma. Immunotherapy has shown promise in other types of cancer. C...
What is the current status of trial NCT03116529?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2017-06-21. Estimated completion is 2024-06-21.
What interventions are being tested in trial NCT03116529?
The interventions under investigation include: Combination Radiation, Immunotherapy, Surgery (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT03116529?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.